9 completed, 6 unknown, 2 terminated, 1 recruiting. 19 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 9, Unknown 6, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 2, Unknown 2, Recruiting 1, Withdrawn 1 |
Follow Dilatation, Pathologic: new trials by email Literature Review of Dilatation, Pathologic trials Research Report on Dilatation, Pathologic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anticholinergics for Cervical Edema in Labor Treatment with Diphenhydramine, Usual Care - Labor Dystocia | Phase 2 / Phase 3 | Recruiting | The University of Texas Health Science Center, Houston | 200 | 2025-03-25 | 2026-05-06 |
| Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle - Mydriasis, Dilation | Phase 3 | Completed | Opus Genetics, Inc | 23 | 2021-12-17 | 2026-10-30 |
| Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle - Mydriasis, Dilation | Phase 3 | Completed | Opus Genetics, Inc | 368 | 2021-11-18 | 2026-10-30 |
| Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo) - Mydriasis, Dilation | Phase 3 | Completed | Opus Genetics, Inc | 185 | 2020-11-18 | 2026-10-30 |
| Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders Ricrolin+, VEGA UV-A system - Keratoconus, Ectasia | Phase 3 | Unknown | Center for Sight, Sacramento, CA | 550 | 2019-03-08 | 2019-02-28 |
| Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block, 20cc 1% lidocaine with 2 units of vasopressin paracervical block - Abortion, Spontaneous, Abortion in First Trimester | Phase 3 | Completed | University of California, San Diego | 114 | 2018-10-29 | 2023-04-20 |
| Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia Ricrolin+, Epi-Off - Keratoconus, Ectasia | Phase 3 | Unknown | Icahn School of Medicine at Mount Sinai | 8 | 2016-06-01 | 2018-06-07 |
| Corneal Cross-Linking Comparing Variables Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam - Unstable Corneas | Phase 3 | Unknown | Crowd Health Research, LTD | 500 | 2014-05-01 | 2014-03-26 |
| Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia Riboflavin, VEGA UV-A Illumination System - Keratoconus and Ectasia | Phase 3 | Terminated | Topcon Medical Systems, Inc. | 500 | 2010-12-01 | 2022-06-29 |
| Safety Study of the VEGA UV-A System to Treat Ectasia VEGA UV-A Illumination System, Riboflavin - Ectasia | Phase 3 | Terminated | Topcon Medical Systems, Inc. | 103 | 2010-12-01 | 2022-06-29 |
| Treatment Study of Frozen Shoulder: Corticosteroid Injection in Joint Versus Wait and See Policy Triamcinolone Acetonide - Shoulder Capsulitis, Shoulder Adhesive Capsulitis | Phase 3 | Unknown | Satya Pal Sharma | 120 | 2010-02-01 | 2015-05-28 |
| Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs Riboflavin - Keratoconus, Ectasia | Phase 2 / Phase 3 | Unknown | Yaron S. Rabinowitz M.D. | 600 | 2009-01-21 | 2018-10-02 |
| Treatment of Keratoconus Using Collagen Cross-Linking Riboflavin-5-phosphate, Sham cross-linking - Keratoconus | Phase 2 / Phase 3 | Unknown | University at Buffalo | 150 | 2008-09-01 | 2009-02-11 |
| Corneal Crosslinking in Keratoconus and Corneal Ectasia Riboflavin, Placebo - Progressive Keratoconus, Corneal Ectasia | Phase 2 / Phase 3 | Withdrawn | Ohio State University | 2008-04-01 | 2017-04-20 | |
| Hysteroscopy After Pretreatment With Misoprostol and Estradiol Trial Misoprostol, Placebo - Cervical Ripening | Phase 3 | Completed | Ullevaal University Hospital | 100 | 2008-01-01 | 2009-05-25 |
| Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia Corneal collagen, Sham comparator - Progressive Keratoconus, Corneal Ectasia | Phase 2 / Phase 3 | Completed | Emory University | 160 | 2007-12-01 | 2010-09-02 |
| Corneal Collagen Cross-Linking for Ectasia (CXL) riboflavin ophthalmic solution, UVA Irradiation - Ectasia | Phase 3 | Completed | Glaukos Corporation | 130 | 2007-12-01 | 2021-04-26 |
| Hysteroscopy and Misoprostol Project misoprostol and cervical ripening - Uterine Hemorrhage | Phase 3 | Completed | Ullevaal University Hospital | 86 | 2006-09-01 | 2007-08-07 |
| A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. AQUAVAN® (fospropofol disodium) Injection - Procedural Sedation | Phase 2 / Phase 3 | Completed | Eisai Inc. | 123 | 2006-05-01 | 2012-06-20 |
Keratoconus (8) · Corneal Diseases (5) · Mydriasis (3) · Abortion, Missed (1) · Abortion, Spontaneous (1) · Arteriovenous Fistula (1) · Bunion (1) · Bursitis (1) · Dystocia (1) · Uterine Hemorrhage (1)
Pathological Conditions, Anatomical (19) · Pathological Conditions, Signs and Symptoms (19) · Eye Diseases (12) · Corneal Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (3) · Pupil Disorders (3) · Urogenital Diseases (3) · Musculoskeletal Diseases (2) · Pregnancy Complications (2) · Arteriovenous Malformations (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Female Urogenital Diseases (1)
Riboflavin (5) · Corneal Cross-Linking (2) · Misoprostol (2) · Cervical Ripening (1) · Diphenhydramine (1) · Flavin Mononucleotide (1) · Injections (1) · Iontophoresis (1) · Lidocaine (1) · Lubricant Eye Drops (1) · Therapeutics (1) · Triamcinolone Acetonide (1) · fospropofol (1)
Opus Genetics, Inc (3) · Topcon Medical Systems, Inc. (2) · Ullevaal University Hospital (2) · Center for Sight, Sacramento, CA (1) · Crowd Health Research, LTD (1) · Eisai Inc. (1) · Emory University (1) · Glaukos Corporation (1) · Icahn School of Medicine at Mount Sinai (1) · Ohio State University (1) · Satya Pal Sharma (1) · The University of Texas Health Science Center, Houston (1) · University at Buffalo (1) · University of California, San Diego (1) · Yaron S. Rabinowitz M.D. (1)
United States (16) · Norway (3)
Anders Barheim, MD PhD (1) · Britt-Ingjerd Nesheim, MD PhD (1) · Britt-Ingjerd Nesheim, MD, PhD (1) · Charles Slonim, MD (1) · Ezra Maguen, M.D. (1) · James B Jones, MD, PharmD (1) · James J Reidy, M.D. (1) · James Salz, M.D. (1) · Nancy A Tanchel, MD (1) · Penny A Asbell, MD (1) · Peter Hersh, MD (1) · R. Doyle Stulting, MD, PhD (1) · Richard Keates, MD (1) · Ronald Gaster, MD (1) · Samantha Antonioli, MD (1)
PMID 41743463, PMID 12719068, PMID 16565005, PMID 16765803, PMID 16900027, PMID 16952090, PMID 17457183, PMID 17457184, PMID 17531694, PMID 17720054, PMID 22692521, PMID 25365551, PMID 27229470, PMID 28865441, PMID 35852274
2008 (1)